1. Home
  2. IXHL vs RFL Comparison

IXHL vs RFL Comparison

Compare IXHL & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$3.92

Market Cap

97.6M

Sector

N/A

ML Signal

HOLD

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.49

Market Cap

61.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IXHL
RFL
Founded
2001
2017
Country
Australia
United States
Employees
N/A
N/A
Industry
Real Estate
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
97.6M
61.1M
IPO Year
2024
2017

Fundamental Metrics

Financial Performance
Metric
IXHL
RFL
Price
$3.92
$1.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.3M
58.8K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.28
EPS
N/A
N/A
Revenue
$12,000.00
$917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.96
52 Week Low
$0.11
$1.12
52 Week High
$5.17
$3.19

Technical Indicators

Market Signals
Indicator
IXHL
RFL
Relative Strength Index (RSI) 89.14 76.62
Support Level $0.32 $1.41
Resistance Level N/A $1.60
Average True Range (ATR) 0.13 0.07
MACD 0.39 0.02
Stochastic Oscillator 76.27 75.61

Price Performance

Historical Comparison
IXHL
RFL

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: